These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 24008770)
1. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients. Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770 [TBL] [Abstract][Full Text] [Related]
2. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376 [TBL] [Abstract][Full Text] [Related]
3. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202 [TBL] [Abstract][Full Text] [Related]
4. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]. Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174 [TBL] [Abstract][Full Text] [Related]
5. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346 [TBL] [Abstract][Full Text] [Related]
7. [Quantification of prame gene transcript in chronic myeloid leukemia]. Zhu ZH; Qian J; Lin J; Qian Z; Yao DM; Wang YL; Chen Q; Xiao GF Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):855-8. PubMed ID: 20723287 [TBL] [Abstract][Full Text] [Related]
8. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. Watari K; Tojo A; Nagamura-Inoue T; Nagamura F; Takeshita A; Fukushima T; Motoji T; Tani K; Asano S FEBS Lett; 2000 Jan; 466(2-3):367-71. PubMed ID: 10682862 [TBL] [Abstract][Full Text] [Related]
9. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453 [TBL] [Abstract][Full Text] [Related]
10. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia]. Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968 [TBL] [Abstract][Full Text] [Related]
11. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Tanaka H; Ito T; Kyo T; Kimura A Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976 [TBL] [Abstract][Full Text] [Related]
12. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636 [TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin and T cell receptor gene rearrangements in Philadelphia chromosome-positive leukemia: a different involvement pattern in blast crisis and acute leukemia. Ohyashiki JH; Ohyashiki K; Tauchi T; Saito M; Nakazawa S; Kimura N; Toyama K Leukemia; 1990 Aug; 4(8):572-9. PubMed ID: 2143795 [TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Serinsöz E; Neusch M; Büsche G; Wasielewski R; Kreipe H; Bock O Br J Haematol; 2004 Aug; 126(3):313-9. PubMed ID: 15257703 [TBL] [Abstract][Full Text] [Related]
15. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia. Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890 [TBL] [Abstract][Full Text] [Related]
17. [Expression of PRAME gene in acute leukemia and its clinical significance]. Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454 [TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]. Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031 [TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644 [TBL] [Abstract][Full Text] [Related]
20. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia. Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]